Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831730 | 0.82 | CDK8 (0.33) | HPGDTSHRMITFALDH1A1TP53 | |
| SCHEMBL9713237 | 0.79 | HPGD (0.33) | HPGDTSHR | |
| SCHEMBL12930817 | 0.77 | HPGD (0.55) | HPGDTSHRMITFALDH1A1TP53 | |
| SCHEMBL20730381 | 0.77 | HPGD (0.32) | HPGDTSHR | |
| SCHEMBL2797934 | 0.77 | PRKAB2 (0.32) | HPGDTSHR | |
| SCHEMBL237855 | 0.76 | CA2 (0.40) | ALDH1A1KMT2AHSD17B10KDM4E | |
| SCHEMBL21847663 | 0.76 | JAK2 (0.32) | — | |
| SCHEMBL14688334 | 0.76 | KMT2A (0.37) | MITFALDH1A1TP53KMT2AHSD17B10 | |
| SCHEMBL16445658 | 0.74 | HPGD (0.30) | HPGDTSHR | |
| SCHEMBL1205789 | 0.73 | HPGD (0.46) | HPGDTSHRKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | claimed |
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | claimed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-2244706-B1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | claimed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | claimed |
| EP-2755652-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | Novartis AG (CH) | 2014-07-23 | — | — | EP | claimed |
| WO-2013038390-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | claimed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | claimed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | claimed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | claimed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | claimed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2008014199-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-31 | — | — | WO | claimed |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| JP-2007518824-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | claimed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | claimed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HPGD 697/4885TSHR 772/4885MITF 2828/4885 |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | CFTR, AQP1, BDKRB1 | HPGD 360/4885TSHR 1212/4885MITF 2313/4885 |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | APP, PARK7, BACE1 | HPGD 2210/4885TSHR 1614/4885MITF 3612/4885 |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | APP, BACE1, PSEN1 | HPGD 3399/4885TSHR 874/4885MITF 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.